Clinical evaluation of bioadhesive hydrogels for topical delivery of hexylaminolevulinate to Barrett's esophagus

Journal of Controlled Release

Volumn 123, Issue 3, 2007, Pages 203-210

  Collaud, S ^a   Warloe, T ^b   Jordan, O ^a   Gurny, R ^a   Lange, N ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Barrett's esophagus; Bioadhesion; Chitosan; Fluorescence diagnosis; Hexylaminolevulinate; Poloxamer

Indexed keywords

BARRETT'S ESOPHAGUS; BIOADHESION; CHITOSAN; FLUORESCENCE DIAGNOSIS; HEXYLAMINOLEVULINATE; HISTOPATHOLOGICAL ANALYSIS; POLOXAMER;

BIOPSY; CARCINOGENS; CROSSLINKING; FLUORESCENCE; POLYACRYLATES;

HYDROGELS;

AMINOLEVULINIC ACID; CARBOMER; CARBOXYMETHYLCELLULOSE; CHITOSAN; DYE; HEXYLAMINOLEVULINATE; HYDROXYPROPYLMETHYLCELLULOSE; LUTROL; POLOXAMER; POLYACRYLIC ACID; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADHESION; ADULT; ANIMAL TISSUE; ARTICLE; BARRETT ESOPHAGUS; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; ESOPHAGUS MUCOSA; FLUORESCENCE; HUMAN; HUMAN EXPERIMENT; HYDROGEL; MALE; MEAN RESIDENCE TIME; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RAT;

ACRYLIC RESINS; ADHESIVENESS; ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ADULT; AMINOLEVULINIC ACID; ANIMALS; BARRETT ESOPHAGUS; CARBON RADIOISOTOPES; CARBOXYMETHYLCELLULOSE; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; COLORING AGENTS; DRUG COMPOUNDING; ESOPHAGOSCOPY; ESOPHAGUS; HUMANS; MALE; METHYLCELLULOSE; MUCOUS MEMBRANE; PERMEABILITY; POLOXAMER; POLYMERS; PROSPECTIVE STUDIES; RATS; RATS, SPRAGUE-DAWLEY; ROSANILINE DYES; SOLUBILITY; TISSUE ADHESIVES;

EID: 35548973900     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2007.08.015     Document Type: Article

References (57)

1. Pera M., Cameron A.J., Trastek V.F., Carpenter H.A., and Zinsmeister A.R. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 104 2 (1993) 510-513
2. Devesa S.S., Blot W.J., and Fraumeni Jr. J.F. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 83 10 (1998) 2049-2053
3. Powell J., and McConkey C.C. The rising trend in oesophageal adenocarcinoma and gastric cardia. Eur. J. Cancer Prev. 1 3 (1992) 265-269
4. Bollschweiler E., Wolfgarten E., Gutschow C., and Holscher A.H. Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer 92 3 (2001) 549-555
5. Sundelof M., Ye W., Dickman P.W., and Lagergren J. Improved survival in both histologic types of oesophageal cancer in Sweden. Int. J. Cancer 99 5 (2002) 751-754
6. Farrow D.C., and Vaughan T.L. Determinants of survival following the diagnosis of esophageal adenocarcinoma (United States). Cancer Causes Control 7 3 (1996) 322-327
7. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002, CA Cancer. J. Clin. 55 2 (2005) 74-108
8. Sabel M.S., Pastore K., Toon H., and Smith J.L. Adenocarcinoma of the esophagus with and without Barrett mucosa. Arch. Surg. 135 7 (2000) 831-835
9. Theisen J., Nigro J.J., DeMeester T.R., Peters J.H., Gastal O.L., Hagen J.A., Hashemi M., and Bremner C.G. Chronology of the Barrett's metaplasia-dysplasia-carcinoma sequence. Dis. Esophagus 17 1 (2004) 67-70
10. Winters Jr. C., Spurling T.J., Chobanian S.J., Curtis D.J., Esposito R.L., Hacker Jr. J.F., Johnson D.A., Cruess D.F., Cotelingam J.D., Gurney M.S., et al. Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology 92 1 (1987) 118-124
11. Haggitt R.C. Barrett's esophagus, dysplasia, and adenocarcinoma. Hum. Pathol. 25 10 (1994) 982-993
12. Lagergren J., Bergstrom R., Lindgren A., and Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N. Engl. J. Med. 340 11 (1999) 825-831
13. Lagergren J. Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk?. Gut 54 Suppl 1 (2005) i1-i5
14. Chow W.H., Blot W.J., Vaughan T.L., Risch H.A., Gammon M.D., Stanford J.L., Dubrow R., Schoenberg J.B., Mayne S.T., Farrow D.C., Ahsan H., West A.B., Rotterdam H., Niwa S., and Fraumeni Jr. J.F. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J. Natl. Cancer Inst. 90 2 (1998) 150-155
15. Sampliner R.E. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The Practice Parameters Committee of the American College of Gastroenterology. Am. J. Gastroenterol. 93 7 (1998) 1028-1032
16. Mayinger B., Reh H., Hochberger J., and Hahn E.G. Endoscopic photodynamic diagnosis: oral aminolevulinic acid is a marker of GI cancer and dysplastic lesions. Gastrointest. Endosc. 50 2 (1999) 242-246
17. Messmann H., Knüchel R., Bäumler W., Holstege A., and Schölmerich J. Endoscopic fluorescence detection of dysplasia in patients with Barrett's esophagus, ulcerative colitis, or adenomatous polyps after 5-aminolevulinic acid-induced protoporphyrin IX sensitization. Gastrointest. Endosc. 49 1 (1999) 97-101
18. Endlicher E., Knuechel R., Hauser T., Szeimies R.M., Scholmerich J., and Messmann H. Endoscopic fluorescence detection of low and high grade dysplasia in Barrett's oesophagus using systemic or local 5-aminolaevulinic acid sensitisation. Gut 48 3 (2001) 314-319
19. Stepinac T., Felley C., Jornod P., Lange N., Gabrecht T., Fontolliet C., Grosjean P., van Melle G., van den Bergh H., Monnier P., Wagnieres G.A., and Dorta G. Endoscopic fluorescence detection of intraepithelial neoplasia in Barrett's esophagus after oral administration of aminolevulinic acid. Endoscopy 35 8 (2003) 663-668
20. Uehlinger P., Zellweger M., Wagnieres G.A., Juillerat-Jeanneret L., van den Bergh H., and Lange N. 5-aminolevulinic acid and its derivatives: physical chemical properties and protoporphyrin IX formation in cultured cells. J. Photochem. Photobiol. B 54 1 (2000) 72-80
21. Batchelor H.K. Novel bioadhesive formulations in drug delivery. Drug Deliv. Companies Autumn/Winter (2004) 16-19
22. Schmolka I.R. Artificial skin. I. Preparation and properties of pluronic F-127 gels for treatment of burns. J. Biomed. Mater. Res. 6 6 (1972) 571-582
23. S. Collaud, Q. Peng, R. Gurny, N. Lange, Thermosetting gel for the delivery of 5-aminolevulinic acid esters to the cervix, J. Pharm. Sci. (in press).
24. Berger J., Reist M., Chenite A., Felt-Baeyens O., Mayer J.M., and Gurny R. Pseudo-thermosetting chitosan hydrogels for biomedical application. Int. J. Pharm. 288 2 (2005) 197-206
25. Lee K.Y., Ha W.S., and Park W.H. Blood compatibility and biodegradability of partially N-acylated chitosan derivatives. Biomaterials 16 16 (1995) 1211-1216
26. Felt O., Furrer P., Mayer J.M., Plazonnet B., Buri P., and Gurny R. Topical use of chitosan in ophthalmology: tolerance assessment and evaluation of precorneal retention. Int. J. Pharm. 180 2 (1999) 185-193
27. Muzzarelli R.A.A., and Rocchetti R. In: Muzzarelli R.A.A., Jeuniaux C., and Gooday G.W. (Eds). Chitin in Nature and Technology (1986), Plenum Press, New York, USA 385-388
28. Reid F., Lobo D.N., Williams R.N., Rowlands B.J., and Allison S.P. (Ab)normal saline and physiological Hartmann's solution: a randomized double-blind crossover study. Clin. Sci. (Lond. ) 104 1 (2003) 17-24
29. Dobrozsi D.J., Smith R.L., and Sakr A.A. Comparative mucoretention of sucralfate suspensions in an everted rat esophagus model. Int. J. Pharm. 189 1 (1999) 81-89
30. Batchelor H.K., Banning D., Dettmar P.W., Hampson F.C., Jolliffe I.G., and Craig D.Q. An in vitro mucosal model for prediction of the bioadhesion of alginate solutions to the oesophagus. Int. J. Pharm. 238 1-2 (2002) 123-132
31. Muranishi S., Okubo Y., and Sezaki H. Manufacture and examination of apparatus for drug release from suppositories. Yakuzaigaku 39 1 (1979) 1-7
32. Harris D.A., and Bashford E.L. Spectrophotometry and Spectrofluorimetry: A Practical Approach (1987), IRL Press, Oxford, England
33. Ortner M.A., Ebert B., Hein E., Zumbusch K., Nolte D., Sukowski U., Weber-Eibel J., Fleige B., Dietel M., Stolte M., Oberhuber G., Porschen R., Klump B., Hortnagl H., Lochs H., and Rinneberg H. Time gated fluorescence spectroscopy in Barrett's oesophagus. Gut 52 1 (2003) 28-33
34. Marti A., Jichlinski P., Lange N., Ballini J.P., Guillou L., Leisinger H.J., and Kucera P. Comparison of aminolevulinic acid and hexylester aminolevulinate induced protoporphyrin IX distribution in human bladder cancer. J. Urol. 170 2 Part 1 (2003) 428-432
35. Lehr C.M. Bioadhesion technologies for the delivery of peptide and protein drugs to the gastrointestinal tract. Crit. Rev. Ther. Drug Carrier Syst. 11 2-3 (1994) 119-160
36. Woodley J. Bioadhesion: new possibilities for drug administration?. Clin. Pharmacokinet. 40 2 (2001) 77-84
37. Marvola M., Vahervuo K., Sothmann A., Marttila E., and Rajaniemi M. Development of a method for study of the tendency of drug products to adhere to the esophagus. J. Pharm. Sci. 71 9 (1982) 975-977
38. Sakkinen M., Marvola J., Kanerva H., Lindevall K., Ahonen A., and Marvola M. Scintigraphic verification of adherence of a chitosan formulation to the human oesophagus. Eur. J. Pharm. Biopharm. 57 1 (2004) 145-147
39. Ponchel G., Touchard F., Duchene D., and Peppas N.A. Bioadhesive analysis of controlled-release systems. I. Fracture and interpenetration analysis in poly(acrylic acid)-containing systems. J. Control. Release 5 2 (1987) 129-141
40. Jacques Y., and Buri P. Optimization of an ex vivo method for bioadhesion quantification. Eur. J. Pharm. Biopharm. 38 (1992) 195-198
41. Jones D.S., Woolfson A.D., and Brown A.F. Textural, viscoelastic and mucoadhesive properties of pharmaceutical gels composed of cellulose polymers. Int. J. Pharm. 151 2 (1997) 223-233
42. Tamburic S., and Craig D.Q. A comparison of different in vitro methods for measuring mucoadhesive performance. Eur. J. Pharm. Biopharm. 44 2 (1997) 159-167
43. Park K. A new approach to study mucoadhesion: colloidal gold staining. Int. J. Pharm. 53 3 (1989) 209-217
44. Kockisch S., Rees G.D., Young S.A., Tsibouklis J., and Smart J.D. A direct-staining method to evaluate the mucoadhesion of polymers from aqueous dispersion. J. Control. Release 77 1-2 (2001) 1-6
45. Vonarx V., Eleouet S., Carre J., Ioss P., Gouyette A., Leray A.M., Merle C., Lajat Y., and Patrice T. Potential efficacy of a delta 5-aminolevulinic acid bioadhesive gel formulation for the photodynamic treatment of lesions of the gastrointestinal tract in mice. J. Pharm. Pharmacol. 49 7 (1997) 652-656
46. Potts A.M., Jackson S., Washington N., Gilchrist P., Ron E.S., Schiller M., and Wilson C. The oesophageal retention of a thermally sensitive hydrogel. J. Pharm. Pharmacol. 49 (1997) 77
47. de Blois A.W., Grouls R.J., Ackerman E.W., and Wijdeven W.J. Development of a stable solution of 5-aminolaevulinic acid for intracutaneous injection in photodynamic therapy. Lasers Med. Sci. 17 3 (2002) 208-215
48. Elfsson B., Wallin I., Eksborg S., Rudaeus K., Ros A.M., and Ehrsson H. Stability of 5-aminolevulinic acid in aqueous solution. Eur. J. Pharm. Sci. 7 2 (1998) 87-91
49. Mortazavi S.A. An in vitro assessment of mucus/mucoadhesive interactions. Int. J. Pharm. 124 2 (1995) 173-182
50. Batchelor H. Bioadhesive dosage forms for esophageal drug delivery. Pharm. Res. 22 2 (2005) 175-181
51. Riley R.G., Green K.L., Smart J.D., Tsibouklis J., Davis J.A., Hampson F., Dettmar P.W., and Wilber W.R. The gastrointestinal transit profile of 14C-labelled poly(acrylic acids): an in vivo study. Biomaterials 22 13 (2001) 1861-1867
52. Soane R.J., Frier M., Perkins A.C., Jones N.S., Davis S.S., and Illum L. Evaluation of the clearance characteristics of bioadhesive systems in humans. Int. J. Pharm. 178 1 (1999) 55-65
53. Nakamura F., Ohta R., Machida Y., and Nagai T. In vitro and in vivo nasal mucoadhesion of some water-soluble polymers. Int. J. Pharm. 134 1-2 (1996) 173-181
54. Kockisch S., Rees G.D., Young S.A., Tsibouklis J., and Smart J.D. Polymeric microspheres for drug delivery to the oral cavity: an in vitro evaluation of mucoadhesive potential. J. Pharm. Sci. 92 8 (2003) 1614-1623
55. Sakkinen M., Marvola J., Kanerva H., Lindevall K., Ahonen A., and Marvola M. Are chitosan formulations mucoadhesive in the human small intestine?: an evaluation based on gamma scintigraphy. Int. J. Pharm. 307 2 (2006) 285-291
56. Pettit M. Treatment of gastroesophageal reflux disease. Pharm World Sci 27 6 (2005) 432-435
57. Nagano H., Machida Y., Iwata M., Imada T., Noguchi Y., Matsumoto A., and Nagai T. Preparation of magnetic granules containing bleomycin and its evaluation using model esophageal cancer. Int. J. Pharm. 147 1 (1997) 119-125